A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard- fractionation radiotherapy for head-and-neck squamous cell carcinomas: First report of RTOG 9003: In regard to fu et al. IJROBP 2000;48:7-16actuarial estimates of late normal-tissue effects . . . now! [1]

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 2, 2001, Pages 563-

  Dubben, Hans Hermann ^a   Beck Bornholdt, Hans Peter ^b  

^a Germany ^*  (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; LETTER; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE III; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION INJURIES; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0035479345     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01661-3     Document Type: Letter

References (5)

1. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard-fractionation radiotherapy for head and neck squamous cell carcinomas; First report of RTOG 9003
2. Transmutatability of dose and time. Commentary on the first report of RTOG 90003
3. Confirmation of improved local-regional control with altered fractionation in head and neck cancer
4. Hyperfractionation; Where do we stand?
5. Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now!